- ►diabetesjournals.org K Winkler, T Konrad, S Füllert, I Friedrich, … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—At baseline, dense LDLs were elevated (apolipoprotein [apo]B in LDL-5
plus LDL-6 >250 mg/l) in 63% of all patients. Sixteen weeks of treatment with
pioglitazone did not significantly change triglycerides, total, LDL, and ... Cited by 91 - Related articles - BL Direct - All 5 versions
- ►uwks.ac.id [PDF] K Winkler, I Friedrich, MW Baumstark, H … - The British Journal of Diabetes & Vascular Disease, 2002 - dvd.sagepub.com Page 1. http://dvd.sagepub.com Disease The British Journal of Diabetes
& Vascular DOI: 10.1177/14746514020020021301 2002; 2; 143 ... Cited by 21 - Related articles - All 3 versions
S Fullert, F Schneider, E Haak, H Rau, K … - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc Hypertension is often associated with insulin resistance, dyslipidemia and
obesity, which indicate a prediabetic state and increased risk of cardiovascular
disease. Pioglitazone treatment of patients with type 2 diabetes reduces ... Cited by 117 - Related articles - All 7 versions
MI Freed, R Ratner, SM Marcovina, MM … - The American journal of cardiology, 2002 - Elsevier This study evaluated the effects of rosiglitazone therapy on lipids and the
efficacy and safety of rosiglitazone in combination with atorvastatin in
patients with type 2 diabetes mellitus. Three-hundred thirty-two patients ... Cited by 167 - Related articles - All 5 versions
- ►endojournals.org K Winkler, C Abletshauser, MM Hoffmann, I … - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc The objective of this study was to determine the effect of slow-release (XL)
fluvastatin on low density lipoprotein (LDL) subfractions in type 2 diabetes. A
multicenter, double-blind, randomized, parallel-group comparison of ... Cited by 40 - Related articles - BL Direct - All 8 versions
- ►ugr.es [PDF] M Herz, D Johns, J Reviriego, LD Grossman, … - Clinical therapeutics, 2003 - Elsevier Results: A total of 297 patients were randomized (99 in each group). Overall,
286 (96.3%) were white. Mean (SD) age was 58.4 (10.9) years (range, 24–85
years), mean (SD) body mass index was 31.4 (4.8) kg/m 2 , mean (SD) ... Cited by 91 - Related articles - All 5 versions
- Free from Publisher CJJ Tack, P Smits, PNM Demacker, AFH … - Diabetes Care, 1998 - Am Diabetes Assoc T he increased risk for card iovascular morbidity and mortality as found in
patients with NIDDM may in part be explained by unfavorable changes in lipop
roteins (1). In NIDDM patients, the majorquantitative change is an ... Cited by 144 - Related articles - BL Direct - All 5 versions
P Gerber, G Lübben, S Heusler, A Dodo - Current Medical Research and Opinion®, 2003 - informahealthcare.com Aim: This Swiss multicentre study examined the efficacy and safety of oral
pioglitazone in patients with type 2 diabetes. Methods: Patients were randomised
to pioglitazone at once-daily doses of 30 mg for 20 weeks (n = 76), 30 mg ... Cited by 44 - Related articles - BL Direct - All 5 versions
- ►ahajournals.org JPH van Wijk, EJP de Koning, EP Martens, TJ … - Arteriosclerosis, thrombosis, and vascular biology, 2003 - Am Heart Assoc We evaluated study population characteristics and treatment effects on blood
lipids between studies in which either rosiglitazone (RSG) or pioglitazone (PIO)
was investigated in patients with type 2 diabetes. We performed a summary ... Cited by 131 - Related articles - BL Direct - All 7 versions
